Patent ID: 11931335
Assignee: AMAZENTIS SA
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 10:
11. A method of treating a condition selected from the group consisting of frailty, muscular atrophy, muscle disuse atrophy, skeletal muscle atrophy or impaired muscle strength associated with aging, and skeletal muscle damage, a mitochondria-related condition associated with altered mitochondrial function or a reduced mitochondrial density, and a condition related to a metabolic function, comprising:
conjointly administering to a vertebrate in need thereof an effective amount of L-carnitine or a pharmaceutically acceptable salt thereof, and a urolithin represented by Formula I or a pharmaceutically acceptable salt thereof;, , wherein:
R1, R2, R3, R4, R5, R6, R7, and R8 are independently selected from the group consisting of H and OR; and
R is independently for each occurrence H, substituted or unsubstituted alkyl, or substituted or unsubstituted aryl.